ArticleBMC infectious diseases2025
Clinical burden and biochemical profiles of viral hepatitis in a tertiary healthcare facility in North Central, Nigeria.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Burden, clinical characteristics, and determinants of neonatal sepsis in a tertiary hospital in North-Central Nigeria: a retrospective study.BMC pediatrics · 2026Article
- A Unified Histopathological Framework of Liver Fibrogenesis in Chronic Viral Hepatitis B, C and Coinfection.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionViral hepatitis remains a significant global health concern, with hepatitis B virus (HBV) and hepatitis C virus (HCV) contributing substantially to chronic liver disease, cirrhosis, and hepatocellular carcinoma. In sub-Saharan Africa, the public health burden of hepatitis is exacerbated by late diagnosis, inadequate monitoring, and limited resources. This study aimed to evaluate liver enzyme levels and their association with demographic factors and clinical severity among hepatitis patients in a tertiary health facility in Nigeria to inform targeted interventions. METHODOLOGY: A retrospective chart study was conducted involving 723 hepatitis patients at Federal Medical Center Keffi, Nigeria. Sociodemographic data were collected alongside laboratory results for alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin. Patients were classified as having HBV, HCV, or HBV/HCV co-infection. Data analysis included descriptive statistics, ANOVA, correlation, and multiple regression models. RESULTS AND DISCUSSION: The majority of patients were aged 18-50 years with three levels (70.1%), with a slight male predominance (54%). Hepatitis B was the most common infection (65%), followed by HCV (23%) and co-infection (12%). Co-infected patients showed the highest mean levels of liver enzymes and total bilirubin (ALT: 210 IU/L, AST: 195 IU/L, ALP: 320 IU/L, bilirubin: 5.5 mmol/L). Clinical severity was positively correlated with all liver markers (r = 0.54-0.65, p < 0.01), and multiple regression analysis confirmed that co-infection and severity of symptoms associated with Hepatitis B were the strongest predictors of elevated liver enzymes. These findings align with global evidence that co-infection accelerates liver damage, and emphasize the need for sex- and age-sensitive screening and early treatment programs.
conclusionThis study highlights the biochemical and demographic characteristics of hepatitis patients in Nigeria, emphasizing the heightened disease severity in co-infected individuals. Integration of liver enzyme monitoring with demographic profiling can improve early diagnosis and resource allocation in hepatitis management. Strengthening public health infrastructure and implementing routine fibrosis assessment are vital to reducing hepatitis-related morbidity in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.